Ask a Doctor
Psoriasis is more of an inconvenience in most cases than it is threatening.
However, it is a chronic systemic inflammatory disease for which there is no true cure. The itching and peeling of skin can lead to significant pain and self-esteem issues. By far, the patient's quality of life is affected most with plaque psoriasis. Self-consciousness and embarrassment about appearance, inconvenience, and high costs of treatment options all affect one's outlook when living with psoriasis. It has recently become apparent that many patients with psoriasis are predisposed to diabetes, obesity, and premature cardiovascular disease.
It is important that such patients seek good overall medical care aside from simply treating their skin disease. Anxiety, depression, or stress may worsen symptoms and increase the tendency to itch. Most patients can expect significant improvement from the treatment of their psoriasis.
Approximately 1%-2% of people in the United States, or about 5.5 million, have plaque psoriasis. Up to 10% of people with plaque psoriasis also have psoriatic arthritis. Individuals with psoriatic arthritis have inflammation in their joints that could result in permanent joint damage if not treated aggressively. It is now becoming apparent that psoriasis is not just a skin disease but can have widespread systemic effects.
Sometimes plaque psoriasis can evolve into more severe disease, such as pustular or erythrodermic psoriasis. In pustular psoriasis, the red areas on the skin contain small blisters filled with pus. In erythrodermic psoriasis, a wide area of red and scaling skin is typical, and it may be itchy and uncomfortable.
For more information, read our full medical article on psoriasis.
Health Solutions From Our Sponsors
Burden, A.D. "Management of psoriasis in childhood." Clin Exp Dermatol 24.5 Sept. 1999: 341-5.
Feely, M.A., B.L. Smith, and J.M. Weinberg. "Novel psoriasis therapies and patient outcomes, part 1: topical medications." Cutis 95.3 Mar. 2015: 164-8, 170.
Greb, Jacqueline E., et al. "Psoriasis." Nature Reviews: Disease Primers 2 Nov. 24, 2016: 1-17.
Jensen, J.D., M.R. Delcambre, G. Nguyen, and N. Sami. "Biologic therapy with or without topical treatment in psoriasis: What does the current evidence say?" Am J Clin Dermatol 15.5 Oct. 2014: 379-85.
Kim, Whan B., Dana Jerome, and Jensen Yeung. "Diagnosis and Management of Psoriasis." Canadian Family Physician 63 April 2017: 278-285.
Mansouri, B., M. Patel, and A. Menter. "Biological therapies for psoriasis." Expert Opin Biol Ther 13.13 Dec. 2013: 1715-30.
Maza, A, et al. "Oral cyclosporin in psoriasis: a systematic review on treatment modalities, risk of kidney toxicity and evidence for use in non-plaque psoriasis." J Eur Acad Dermatol Venereol 25 Suppl 2 May 2011: 19-27.
Michalek, I.M., B. Loring, and S.M. John. "A Systematic Review of Worldwide Epidemiology of Psoriasis." JEADV 2016: 1-8.
Paul, C., et al. "Evidence-based recommendations on conventional systemic treatments in psoriasis: systematic review and expert opinion of a panel of dermatologists." J Eur Acad Dermatol Venereol 25 Suppl 2 May 2011: 2-11.
Sbidian, E., et al. "Efficacy and safety of oral retinoids in different psoriasis subtypes: a systematic literature review." J Eur Acad Dermatol Venereol 25 Suppl 2 May 2011: 28-33.
van de Kerkhof, P.C. "An update on topical therapies for mild-moderate psoriasis." Dermatol Clin 33.1 Jan. 2015: 73-7.
Villaseñor-Park, Jennifer, David Wheeler, and Lisa Grandinetti. "Psoriasis: Evolving Treatment for a Complex Disease." Cleveland Clinic Journal of Medicine 79.6 June 2012: 413-423.